Apimeds Pharmaceuticals US (APUS) Non Operating Income (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) reported Non Operating Income of $5.9 million for Q4 2025, up 16437.48% on a YoY basis from N/an in Q4 2024, and up 9243.26% quarter-over-quarter from $62984.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Non Operating Income (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Non Operating Income for 2 years, with the latest figure at $5.9 million in Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 16437.48% year-over-year to $5.9 million; the trailing twelve-month figure through Dec 2025 stood at $5.9 million (up 5245.07% YoY), and the FY2025 full-year result was $5.9 million, up 5245.07% from the prior year.
  • Non Operating Income for Q4 2025 stood at $5.9 million, up from $62984.0 in the prior quarter.
  • The five-year high for Non Operating Income was $5.9 million in Q4 2025, with the low at -$38029.0 in Q1 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn -216.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 20.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn -7.50 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -504,111.66
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 53.40 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -13.65 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -23.23 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 5.71 Mn
10 Apimeds Pharmaceuticals US 13.93 Mn 10.29 Mn - 5.88 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 5.88 Mn
Sep 30, 2025 62,984.00
Jun 30, 2025 1,711.00
Mar 31, 2025 -38,029.00
Dec 31, 2024 -36,020.00
Sep 30, 2024 -32,522.00
Jun 30, 2024 -21,606.00
Mar 31, 2024 -24,747.00